| Literature DB >> 29147974 |
Rasoul Baharlou1, Bizhan Romani2,3, Seyed Jalal Kiani4, Kaveh Sadeghi5, Enayatollah Shadmand1, Hadi Fazel6, Farid Azizi Jalilian7, Ebrahim Kord5, Sajad Yaghoubi8, Yousef Nikmanesh5, Abbas Ahmadi Vasmehjani9,10.
Abstract
Hepatitis C virus (HCV) modulates immune-related inflammatory responses to induce milder reactions leading to virus persistence. In this regard, the present study aimed to investigate the link between the HCV genotypes and the proinflammatory and regulatory cytokine levels. Ninety patients with hepatitis C infection (68 treatment-naive and 22 treated patients) and 76 healthy blood donors were studied. The serum levels of IFN-γ, IL-10, IL-17A, and IL-21 were measured by ELISA in the patients and healthy controls. IL-10, IL-17A, and IL-21 levels were significantly higher in HCV patients than in the healthy controls. The same cytokines were also higher in genotype 3a-infected patients compared with genotype 1a-infected patients. Interestingly, in treated patients, lower serum levels of IL-17A and IL-21 were detected in G3a-infected individuals, but not in those infected with G1a. G3a viral load displayed a significant correlation with IL-21 and IL-17A levels. In addition, G1a viral load correlated with IL-10 levels. In G3a-infected patients, a significant association was found between IL-17A serum levels and ALT. We found differences in IL-21 and IL-17A serum levels among HCV-infected patients which were genotype dependent. Since Th17-associated cytokines are associated with the progression of liver disease in HCV patients, IL-17A and IL-21 can be used as important biological markers for evaluating the immunopathogenesis of chronic hepatitis. Our results suggest that HCV G3a along with immune responses such as cytokines in HCV patients should be taken into account when interpreting clinical data and IFN-based therapeutic response.Entities:
Keywords: Antiviral treatment; Cytokines; Hepatitis C genotype; Inflammatory
Mesh:
Substances:
Year: 2017 PMID: 29147974 DOI: 10.1007/s00430-017-0527-9
Source DB: PubMed Journal: Med Microbiol Immunol ISSN: 0300-8584 Impact factor: 3.402